helloKKK

keep fit

[helloKKK @helloKKK10]

#Verda City
我已经申请了 #Verda 公民。 我很开心能成为构建Verda City生态系统的社区的一员。
加入 #Verda City ，免费领取你的价值代币
https://t.co/kJVSVRr0F6

[Freda Duan @FredaDuan]

AI Drug Discovery Is Becoming a Bottleneck Trade

I get excited when an industry starts going through a real regime change. AI drug discovery (“AIDD”) increasingly looks like one of those moments.

Two things are happening:
1/ Upstream: the frontier AI labs are piling in.
2/ Downstream: The supply chain is clearly moving.

Supply-chain checks suggest the upstream picks-and-shovels of discovery and early preclinical R&D are starting to feel the increase in experimental volume.

DNA → protein → assays → sequencing → automation → preclinical testing

Names across that stack include $TWST , @GenScript , $ILMN , $TXG , lab-automation vendors and CROs.

$TWST expects triple-digit percentage growth in AI-enabled drug-discovery orders in FY26, and another year of triple-digit order growth in FY27.

@GenScript's AIDD business doubled YoY in 1H26. Its current platform advertises industrial-scale validation of 4,000+ designs/day, with integrated sequence-to-data workflows. Our channel checks suggest the ramp is moving even faster: roughly 8,000 designs/day currently, with a path toward ~16,000/day by YE26.

---
Why does AI drive more wet-lab demand?

1/ AI makes hypothesis generation almost free → way more shots on goal.
The bottleneck is moving from expert-driven design to biological validation.

2/ AI models need continuous experimental feedback — and both good and bad data are useful.
Traditionally, only the highest-conviction A+ candidates might get pushed into expensive validation. With AI, even the B/C candidates can be valuable because failed experiments generate training data.

@GenScript has said its sequence-to-binding workflow can return data in 4–7 days, and that faster cycle times matter because AI models depend on continuous experimental feedback.

@Anthropic is a clean example. @claudeai designed 1,320 protein binders. @adaptyvbio converted those digital sequences into DNA, expressed the proteins and tested binding. Only 354 actually bound. And the 966 failures are not wasted. They are useful negative labels: what does not express, what does not bind, what has poor affinity. Those results help train the next model iteration.

3/ Wet labs are no longer just making drugs. They are making training data.
$TWST / @GenScript increasingly look like biological data foundries.

$TWST explicitly talks about generating model-ready data from AI-designed sequences. In some workflows, the customer may care less about receiving the physical protein than about getting structured experimental results back into the model.

Traditional drug discovery asks: “Does candidate X work?”

AI drug discovery also asks: “What can this experiment teach the model?”

---
TAM of AIDD

If AI is simply a better R&D tool, the relevant spending pool is the $300–400B of annual global pharma R&D. If AI meaningfully increases the number of viable drug programs, the opportunity is larger because it expands downstream demand for DNA synthesis, protein production, assays, and preclinical work.

Near term, we can also size demand from AI-company spending. If Anthropic reaches $80B of ARR in 2026 and spends just 1% on AIDD, that alone would imply ~$800M of annual investment.

---
Trade setup

This is a trade that could have long legs. It’s hard to really stop working until PhaseI/II results (2028+)

It smells a lot like the bottleneck trade we just saw in semis: GPUs → HBM → networking → power/cooling. In biology, It basically follows the drug discovery process downstream: AI models → designs → DNA/protein → assays → preclinical capacity.

After the upstream picks-and-shovels, animal testing could become the next bottleneck. Monkey prices are already near prior highs and CRO capacity is tight. AIDD pushing more candidates into preclinical development would only add demand.

?? But clinical trials are still the bottleneck?
This is the biggest pushback I keep coming back to. No matter how fast discovery becomes, drugs still need to go through preclinical → Phase I → Phase II → Phase III → approval. You still need patients, time and capital.

But that doesn’t mean the bottleneck trade won’t work. More viable candidates — especially with higher success rates — still means more demand throughout the development process.

And who knows: clinical trials themselves may eventually be optimized by AI.

?? What breaks the trade?
Near term, the picks-and-shovels trade breaks if experimental budgets stop growing, AI-generated designs don’t translate into useful wet-lab hits, or capacity catches up too quickly.

Longer term, the thesis breaks if AI drugs look great in discovery / Phase I but fail at normal rates in Phase II/III. That is why Phase II matters so much.

?? Milestones
Late 2026–2027: first Isomorphic-designed drugs enter human trials; more AI-native programs move into IND-enabling work / tox.

2028–2030: clinical trial results start telling us whether AI-designed drugs actually perform better than conventional drugs.

Calling all the "bottleneck bros". :) @jukan05 @zephyr_z9 @aleabitoreddit @ParadisLabs

+++
More comprehensive analysis: https://t.co/vaTuiyyYB6

[Elon Musk @elonmusk]

SpaceX is a super intelligence company

[helloKKK @helloKKK10]

@elonmusk from 2020 i believe tesla is a super intelligence company

[helloKKK @helloKKK10]

@eth2060 hi

[helloKKK @helloKKK10]

@elonmusk When will it be ready for mass production?

[helloKKK @helloKKK10]

@AshleyDCan good time

[helloKKK @helloKKK10]

@netcapgirl Only people working on the front line of engineering can truly understand whether AI can actually replace humans.

[helloKKK @helloKKK10]

@piggy1627 $10000. send my bnb chain：0x391c992838cfc07c4fc026d55f44a8ef03a86935

[helloKKK @helloKKK10]

@egg_ehh hollo gey 0x391c992838cfc07c4fc026d55f44a8ef03a86935

[helloKKK @helloKKK10]

@shiyi_peng @ycombinator u have skill to find something right

[helloKKK @helloKKK10]

@PrinceOmarX $10000 u can send my bnb chain：0x391c992838cfc07c4fc026d55f44a8ef03a86935

[helloKKK @helloKKK10]

@SpaceX sky is anywhere

[helloKKK @helloKKK10]

@elonmusk i will get one modely

[helloKKK @helloKKK10]

@SpaceX beautiful

[helloKKK @helloKKK10]

@ViewsOfChris nice

[helloKKK @helloKKK10]

@KhalidAlNumi fuck u

[helloKKK @helloKKK10]

@elonmusk hhhhh

[helloKKK @helloKKK10]

I feel that the American emperor is playing a big game of chess.

If the foreign war doesn't work, focus on finance and harvest fattened pigs.

Internally, it is more and more moving towards nationalization, ensuring safety and risk removal.

The lighthouse ran to the moon and Mars with the world's technology. It's not good to say that it was followed and found that it was not the case.

For half a century, human beings have indeed no technology that can bring human prosperity forward. If AI can, it will also make a major breakthrough in mathematics, physics, biochemicals. AI is applied to industrial automation on a large scale and completely changes the labor structure.

The singularity has not reached yet. Everyone is expecting the singularity to come soon. Maybe it will be many years. Maybe it will come soon tomorrow.

On the other side of U.S. stocks, semiconductor technology is frantically killing financing leverage. Storage can't be suppressed, but it can't produce practical application benefits on a large scale. It can only be lured back and forth to go short.

Now the Internet is spreading too fast, and the traffic may be too crazy. Invisibly, it has accelerated the explosion point. People may be crazy just to live a good life, even if they are alone.

[helloKKK @helloKKK10]

@elonmusk When will intelligent agents be able to build rockets?

[helloKKK @helloKKK10]

@karpathy very nice idea